Lantern Pharma (LTRN) Tops Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
March 20, 2023 4:01 PM EDTThe Harmonic clinical trial, a Phase 2 study in never-smoker patients with non-small lung cancer, has activated 5 clinical trial sites, across 12 locations, and anticipates multiple additional sites in the US during the 1st half of 2023; first enrolled patients are anticipated for Q2 2023. IND-enabling studies for LP-184 are completed, and submission of the IND application to the FDA is anticipated for April 2023. Completion of IND-enabling studies for LP-284 and submission of the IND application to the FDA are anticipated in mid-2023. First-in-human Phase 1 clinical trials for LP-184, in genomically defined solid tumors, and for LP-284,... More
